ProKidney Q2 EPS $(0.16) Beats $(0.17) Estimate; Ended The Second Quarter With $431.5M In Cash And Cash Equivalents
Portfolio Pulse from Benzinga Newsdesk
ProKidney (NASDAQ:PROK) reported Q2 EPS of $(0.16), beating the $(0.17) estimate. The company ended the quarter with $431.5M in cash and equivalents, despite a 14.29% increase in losses compared to the same period last year.
August 09, 2024 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProKidney reported Q2 EPS of $(0.16), beating the $(0.17) estimate. The company ended the quarter with $431.5M in cash and equivalents, despite a 14.29% increase in losses compared to the same period last year.
ProKidney's Q2 EPS beat analyst estimates, which is generally positive news for the stock. However, the increase in losses compared to the same period last year may temper investor enthusiasm. The substantial cash reserves provide a cushion for future operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100